BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17003916)

  • 1. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.
    Weber AA; Hohlfeld T; Harder S
    Thromb Haemost; 2006 Oct; 96(4):413-6. PubMed ID: 17003916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.
    Antman EM; Bennett JS; Daugherty A; Furberg C; Roberts H; Taubert KA;
    Circulation; 2007 Mar; 115(12):1634-42. PubMed ID: 17325246
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacology of selective inhibition of COX-2.
    Grosser T
    Thromb Haemost; 2006 Oct; 96(4):393-400. PubMed ID: 17003913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
    Cen YY
    Circulation; 2007 Mar; 115(12):e348; author reply e349. PubMed ID: 17389275
    [No Abstract]   [Full Text] [Related]  

  • 7. NSAID-induced gastrointestinal and cardiovascular injury.
    Ng SC; Chan FK
    Curr Opin Gastroenterol; 2010 Nov; 26(6):611-7. PubMed ID: 20948372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What price pain relief?
    Hochman JS; Shah NR
    Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335
    [No Abstract]   [Full Text] [Related]  

  • 10. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
    Maree AO; Fitzgerald DJ
    Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin resistance: does it exist and is it an important clinical problem?
    Eikelboom J
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):268-70. PubMed ID: 16728937
    [No Abstract]   [Full Text] [Related]  

  • 16. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective COX-2 inhibitors: a promise unfulfilled?
    Henry D; McGettigan P
    Gastroenterology; 2007 Feb; 132(2):790-4. PubMed ID: 17261306
    [No Abstract]   [Full Text] [Related]  

  • 18. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
    Scheiman JM
    Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future.
    Fiorucci S
    Gastroenterol Clin North Am; 2009 Jun; 38(2):315-32. PubMed ID: 19446261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.